AstraZeneca在与中国共同开发的2B交易中获得了Jacobio癌症药物JAB-23E73的全球权益。 AstraZeneca acquires global rights to Jacobio’s cancer drug JAB-23E73 in a $2B deal, with co-development in China.

中国生物技术公司Jacobio Pharma向AstraZeneca颁发了其实验性Pan-KRAS抑制剂JAB-23E73许可证,价值达20亿美元,其中包括一笔1亿美元的预付付款和可能的里程碑付款。 Chinese biotech firm Jacobio Pharma has licensed its experimental pan-KRAS inhibitor JAB-23E73 to AstraZeneca in a deal worth up to $2 billion, including a $100 million upfront payment and potential milestone payments. AstraZeneca公司在中国大陆以外获得专有权利,而两家公司将在中国共同开发和销售该药物。 AstraZeneca gains exclusive rights outside mainland China, while both companies will co-develop and market the drug in China. 第一阶段药物针对KRAS突变,这种突变在胰腺癌、直肠癌和肺癌中常见,影响约23%的癌症。 The Phase I drug targets KRAS mutations, common in pancreatic, colorectal, and lung cancers, affecting about 23% of all cancers. Jacobio选择AstraZeneca作为全球推广对象,并选用肿瘤学专门知识来推进复方疗法。 Jacobio selected AstraZeneca for its global reach and oncology expertise to advance combination therapies. 尽管这项交易意义重大,但Jacobio的股票在宣布后下跌了13%以上,一些投资者质疑预付成本,尽管该公司认为估值是合理的,并强调了长期科学目标。 Despite the deal’s significance, Jacobio’s shares dropped over 13% post-announcement, with some investors questioning the upfront cost, though the company defended the valuation as reasonable and emphasized long-term scientific goals.